Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition

Teva Pharmaceutical TEVA on Thursday released its 2015 outlook.

Here are some of the business-related highlights:

• Foreign exchange rates are expected to have a $700 million adverse impact on revenues.
• Copaxone 20 mg/mL is expected to face two AB-rated generic competitors in the U.S. beginning in September.
• Copaxone 40 mg/mL will be launched in the European Union and elsewhere in the first quarter.
• Generic Pulmicort will see additional generic competition in the first of the year, resulting in a decrease of revenues by $400 to $500 million, and a decrease in operating profit of $100 to $200 million from 2014 levels.

Here are some of the financial-related highlights:

• Net revenue of $19.0 to $19.4 billion.
• Operating Income of $5.7 to $5.9 billion.
• Earnings per share of $5.00 to $5.30.
• Cash flow from operations of $4.3 billion to $4.7 billion.
• Free cash flow of $3.5 billion to $3.7 billion.
• Company will spend $1 billion to $1.2 billion share buybacks.

A conference call and webcast was hosted by the company on Thursday at 8:00 a.m. A replay of the webcast will available within 24 hours on the company's website.